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Abstract. DNA intrastrand cross-linking agents such as oxali-
platin induce DNA double-strand breaks (DSBs) during DNA 
repair and replication. In the present study, we hypothesized 
that DNA intrastrand cross-linking agents may significantly 
benefit colorectal cancer patients with deficiencies in DSB 
repair. Seventy-eight patients with metastatic or recurrent 
colorectal cancer who had measurable target lesions and who 
underwent resection for primary colorectal cancer in our insti-
tution between April 2007 and March 2013 were included in the 
present study. The median age was 64.5 years, and the cohort 
consisted of 49 males and 29 females. The median progression-
free survival (PFS) was 10.9 months. The expression of DSB 
repair proteins such as RAD51 and MRE11 was investigated 
by immunohistochemistry, and associations between RAD51 
and MRE11 expression and clinicopathological factors or 
chemotherapeutic effect were assessed. MRE11-negative cases 
and RAD51-negative cases achieved significantly better tumor 
reduction compared with cases with positive expression. Cases 
with negative expression of both proteins or negative expres-
sion of either protein had significantly longer PFS than cases 
with positive expression for both proteins. In conclusion, DSB 
repair protein expression-negative colorectal cancer cases may 
be more highly sensitive to chemotherapy, and thus DSB repair 
protein expression may be a useful prognostic indicator for 
colorectal cancer patients.
Introduction
Remarkable progress has been made in chemotherapy for 
colorectal cancer during the last decade. Currently, standard 
first-line treatments for unresectable advanced or recurrent 
colorectal cancer include fluorouracil with irinotecan or oxali-
platin, alone or in combination with molecular-targeted agents, 
such as the monoclonal antibody against vascular endothelial 
growth factor (VEGF) and epidermal growth factor receptor 
(EGFR) (1,2). Combinations of drug therapies in unresectable 
advanced or recurrent colorectal cancer patients has prolonged 
the survival time to more than 30 months (3-5), but the thera-
peutic effects vary depending on each case. Thus, it is important 
to predict the chemotherapeutic effect and select patients 
who will benefit from cancer chemotherapy. Several studies 
have shown that various biomarkers predict the sensitivity 
to chemotherapy or chemoradiation therapy. The presence of 
microsatellite instability (MSI) and mutations of the KRAS 
gene are reliable biomarkers for sensitivity to fluorouracil and 
anti-EGFR monoclonal antibodies, respectively (5,6). However, 
there is no reliable biomarker for oxaliplatin and irinotecan.
DNA intrastrand cross-linking agents such as oxali-
platin induce DNA double-strand breaks (DSBs) during the 
process of DNA replication and repair (7). BRCA1, 2, the 
MRE11-RAD50-NBS1 (MRN) complex and RAD51 play 
an important role in homologous recombination during 
DSB repair. A previous study showed that DNA damage 
repair competence varies among individual breast tumors, 
and is closely correlated with chemosensitivity (8). The 
Fanconi anemia-BRCA pathway plays an important role in 
restoring cytotoxic damage by anticancer agents and radia-
tion (9,10). Furthermore, previous studies have shown that 
BRCA-associated cancer is particularly sensitive to DNA 
interstrand cross-linking agents such as mitomycin C or 
platinum-based drugs (11,12). Differences in the expression of 
DNA DSB repair proteins (DDRPs) among individual colon 
cancer cases may also be related to the sensitivity to treatment, 
as well as breast cancer.
MRE11 forms the core of the MRN complex, which has 
essential roles in detection, signaling, protection and repair of 
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DSBs (13,14). RAD51 is an important factor in homologous 
recombination as well as MRE11, and is a predictive factor for 
chemoradiotherapy response in a variety of human cancers. 
Moreover, overexpression of RAD51 confers resistance to 
DNA interstrand cross-linking agents such as cisplatin in non-
small cell lung cancer (15-17).
In the present study, we hypothesized that DNA intrastrand 
cross-linking agents may significantly benefit colorectal cancer 
patients with deficiencies in DSB repair. We investigated the 
expression of MRE11 and RAD51 by immunohistochemistry. 
Associations between expression and therapeutic effect in 
colorectal cancer patients were also explored.
Materials and methods
Patients. Seventy-eight patients with metastatic or recurrent 
colorectal cancer who had measurable target lesions such as 
hepatic, pulmonary, lymphatic and peritoneal metastases, 
underwent resection for primary colon and rectal cancer 
at our institution between April 2007 and March 2013. All 
patients underwent combination chemotherapy including 
oxaliplatin.
Assessments of therapeutic effect. Descriptions of the thera-
peutic effects were evaluated using the best overall response 
to first-line chemotherapy using RECIST version 1.1. Changes 
in tumor size were expressed as the relative change in the 
sum of the longest diameters of the target lesions. Non-target 
lesions and newly occurring lesions were not considered in 
the measurement of tumor size changes (18). The endpoints of 
the long-term outcome study were progression-free survival 
(PFS). PFS was calculated by progression of target lesions as 
the only events for survival analyses.
Immunohistochemistry. Five-micrometer sections were 
deparaffinized with xylene and rehydrated with alcohol, and 
placed in 0.1 M NaOH citrase buffer (pH 7.0) for RAD51 
immunostaining or 0.01 M NaOH citrate buffer (pH 6.0) for 
MRE11 immunostaining, and heated in an autoclave at 121˚C 
for 15 min. Sections were then preincubated with 3% H2O2 in 
methanol for 30 min at room temperature to quench endog-
enous peroxidase activity. After blocking with normal goat 
serum, the sections were incubated with mouse anti-RAD51 
3C10 monoclonal antibody (1:800; clone 51RAD01; Thermo 
Scientific, Fremont, CA, USA) and mouse anti-MRE11 12D7 
monoclonal antibody (1:1600; ab214; Abcam, Cambridge, 
UK) for 60 min at 4˚C. Thereafter, the sections were incu-
bated with a secondary antibody (Vectastain Elite ABC kit; 
Vector Laboratories, Burlingame, CA, uSA) for 30 min, 
washed with phosphate-buffered saline (PBS) and treated 
with peroxidase-conjugated streptavidin for 30 min. The 
sections were visualized by incubation with diaminobenzi-
dine tetrahydrochloride (Liquid DAB+ Substrate Chromogen 
System; Dako, Carpinteria, CA, uSA) and counterstained 
with hematoxylin.
Evaluation of immunohistochemical staining. Immuno-
histochemistry (IHC) scores for <10% of nuclear staining 
in cancer cells were negative, whereas those cases with IHC 
scores for >10% stained cells were deemed positive.
Statistical analysis. Categorical analysis of variables was 
performed using either the Chi-square or Fisher's exact 
test, as appropriate. Continuous data were compared with 
the Mann-Whitney U test. Survival curves were plotted 
according to the Kaplan-Meier method, and any differ-
ences were analyzed using the log-rank test. A multivariate 
analysis with Cox proportional hazards model was adopted 
to clarify the independent prognostic factors. Differences 
were considered to be significant if the P-value was <0.05. 
All statistical analyses were carried out using the R software 
(version 3.1.1).
Results
Patient clinicopathological characteristics. Patient clinical 
characteristics are detailed in Table I. The median age 
was 64.5 years, and the cohort consisted of 49 males and 
29 females. Most patients received combination chemotherapy 
in addition to bevacizumab (n=70, 90%). Fifty patients 
received mFOLFOX6 + bevacizumab and 20 patients received 
CapeOX + bevacizumab. The median PFS was 10.9 months.
Table I. Clinicopathological characteristics of the patients 
(n=78).
Factors Date
Median age (years) 64.5
Gender, n
  Men 49
  Female 29
Location, n
  Proximal 20
  Distal 58
Median tumor size (mm) 50
Histology, n
  Well differentiated 25
  Moderately differentiated 44
  Poorly differentiated 4
  Others 5
Site of metastases, n
  Liver 44
  Lung 21
  Peritoneum 11
  Lymph node 8
  Bone 1
Regimen, n
  mFOLFOX6 + bevacizumab 50
  CapeOX + bevacizumab 20
  mFOLFOX6 7
  CapeOX 1
Treatment cycles, mean number 10
Median overall survival (months) 32.5
Median progression-free survival (months) 10.9
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MRE11 expression and clinical outcome. Positive nuclear 
staining of MRE11 was observed in 48 (61.5%) of the 
78 cases (Fig. 1A). The association between MRE11 
expression and clinicopathological characteristics is shown in 
Table II. There was no significant association between MRE11 
expression and age, tumor location or tumor size. Male gender 
and undifferentiated type tended to be associated with MRE11 
positivity. There was no significant association between 
MRE11 expression and CEA reduction ratio. MRE11-negative 
cases had significantly better relative change compared with 
MRE1-positive cases. Thus, MRE11-negative cases achieved 
better size reduction of the target lesion when compared with 
MRE11-positive cases. The association between MRE11 
expression and prognosis is shown in Fig. 2A. MRE11-
positive cases exhibited poorer PFS when compared with 
MRE11-negative cases, but no significant association was 
identified between MRE11 expression and PFS.
RAD51 expression and clinical outcome. Positive nuclear 
staining of RAD51 was observed in 40 (51.2%) of the 78 cases 
(Fig. 1B). There was no significant association between 
RAD51 expression and age, gender, tumor location, tumor 
Table II. Relationship between DDRP expression and clinicopathological characteristics of the patients (n=90).
 MRE11 RAD51
 ------------------------------------------------- -------------------------------------------------
 Negative Positive  Negative Positive
Factors (n=30) (n=48) P-value (n=38) (n=40) P-value
Median age (years) 64 65.5 0.2 64 67 0.3
Gender
  Male 15 34 0.064 26 23 0.3
  Female 15 14  12 17
Location
  Proximal 10 10 0.2 9 11 0.7
  Distal 20 38  29 29
Median tumor size (mm) 55 50 0.4 55 50 0.2
Median treatment cycles 11.5 9.5 0.2 11.5 8 0.1
Histological type
  Differentiated 29 40 0.080 35 34 0.3
  undifferentiated 1 8  3 6
Median serum CEA level (ng/ml)
  Before treatment 6.6 21.05 0.045 7.25 22.35 0.07
  3 months later 5.25 10.1 0.047 4.45 12.65 0.003
CEA reduction ratio 0.70 0.61 0.4 0.50 0.76 0.033
Relative change 0.65 0.92 0.029 0.48 1.01 <0.001
DDRP, DNA double-strand break repair protein; CEA, carcinoembryonic antigen.
Figure 1. MRE11 and RAD51 expression in colorectal cancer tissues as assessed by immunohistochemistry. (A) MRE11 was stained in the nucleus in the 
cancer cells (magnification, x400). (B) RAD51 was stained in the nucleus in the cancer cells (magnification, x400).
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size or histological type (Table II). RAD51-negative cases had 
significantly better CEA reduction ratios and relative change. 
RAD51-positive cases had significantly poorer PFS when 
compared with RAD51-negative cases (Fig. 2B). However, for 
multivariate analysis, RAD51 was not an independent prog-
nostic factor (Table III).
DSB repair protein expression pattern. In the DSB repair 
pathway, the role of MRE11 and RAD51 are sequential. When 
one of either is defect, it may be impossible to recovery from 
DSBs. Therefore, we defined two groups. The ‘defective 
pattern’ is described as the state when expression of both 
MRE11 and RAD51 expression is negative or expression of 
either one of these protein is negative. The ‘abundant pattern’ 
is described as the state when expression of both proteins is 
positive. In addition, we investigated the association between 
the two groups and therapeutic effect. The association 
between expression patterns and clinical characteristics or 
chemotherapeutic effect is shown in Table IV. None of the 
examined clinicopathological characteristics correlated with 
the expression pattern. For the therapeutic effects, there was 
no significant difference between expression pattern and 
CEA reduction ratio. The defective pattern had significantly 
better relative change compared with the abundant pattern. As 
shown in Fig. 2C, the median PFS for the defective pattern 
and abundant pattern was 13.2 and 10.1 months, respectively, 
and there was a significant difference between the defective 
pattern and abundant pattern for PFS (Fig. 2C). Nonetheless, 
for the multivariate analysis, the expression pattern or 
RAD51 expression alone were not independent prognostic 
factors (Table III).
Distal colon cancer patients benefit more from these ex vivo 
tests. MRE11 mutations occur in 83.7% of MMR-defective 
primary colorectal cancers. MSI is displayed in ~15% of 
colorectal cancer cases. We reviewed all subjects in the present 
study with the exception of one case of tumor localization to 
a site proximal to the splenic flexure due to the association 
of high-frequency MSI with this tumor site. In these cases, 
MRE11-negative cases exhibited longer PFS than the positive 
cases (P=0.077) (Fig. 2D). Moreover, by multivariate analysis, 
DSB repair protein expression pattern was an independent 
prognostic factor (P=0.036) (Table V).
Discussion
The recent development of chemotherapies such as FOLFOX 
and FOLFIRI along with several molecular-targeting 
agents has markedly improved the survival of unresectable 
colorectal cancer patients. Previous studies have shown that 
the median survival time was prolonged to 11-26 months in 
unresectable advanced or recurrent colorectal cancer (19,20). 
In the present study, we calculated the curative effect of 
chemotherapy by determining the correlations between 
DSB repair protein expression pattern and chemotherapeutic 
effect; those patients exhibiting better relative changes in 
Figure 2. Kaplan-Meier progression-free survival curves of colon cancer patients. (A) MRE11 expression status in all cases (P=0.5). (B) RAD51 expression 
status in all cases (P=0.035). (C) DSB repair protein expression pattern in all cases (P=0.015). (D) MRE11 expression status in distal colon (P=0.077).
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tumor size had longer survival times. According to a previous 
study, the chemotherapeutic effect by first-line treatment may 
be a prognostic factor. Therefore, it is necessary to detect 
biomarkers that predict the effect of first-line treatment to 
obtain further chemotherapeutic effects.
Oxaliplatin is a DNA intrastrand cross-linking agent and 
is frequently used to treat colorectal cancer that has spread. 
Table IV. Relationship between the DSB protein expression 
pattern and clinicopathological characteristics.
 Defective Abundant
Factors (n=47) (n=31) P-value
Median age (years) 64 68 0.3
Gender, n
  Male 30 19 0.8
  Female 17 12
Location, n
  Right 13 7 0.8
  Left 34 24
Median tumor size (mm) 55 50 0.6
Median treatment cycles 11 8 0.1
Histological type, n
  Differentiated 44 25 0.08a
  undifferentiated 3 6
Median serum CEA level
(ng/ml)
  Before treatment 7 24 0.009
  3 months later 4.7 12.8 0.001
CEA reduction ratio 0.55 0.68 0.1
Relative change 0.5 1.02 <0.001
DSB, DNA double-strand break.
Table III. univariate and multivariate analyses for progres-
sion-free survival.
 univariate Multivariate
 ----------------------------- ----------------------------------------------
 Median  HR
Factor PFS P-value (95% CI) P-value
  Age (years)
  >60 11.8 0.8
  ≤60 10.6
Gender
  Male 13.2 0.070
  Female 10
Location
  Proximal 9.3 0.002 0.56 (0.31-1.00) 0.051
  Distal 13.5
Tumor size (mm)
  <50 11.3 0.5
  ≥50 11.3
Histology
  undifferentiated 11.8 0.1
  Differentiated 9.7
Treatment cycles
  <10 6.4 0.005 0.49 (0.30-0.80) 0.005
  ≥10 14.2
CEA reduction ratio
  <0.6 11.3 0.4
  ≥0.6 11.3
Relative change
  <0.7 18.4 <0.001 2.53 (1.39-4.62) 0.002
  ≥0.7 9,0
MRE11
  Negative 11.8 0.5
  Positive 11.3
RAD51
  Negative 13.5 0.035 0.80 (0.35-1.83) 0.6
  Positive 9.7
DSB repair protein
expression pattern
  Defective 13.2 0.015 1.39 (0.58-3.34) 0.5
  Abundant 10.1
HR, hazard ratio; PFS, progression-free survival; CI, confidence 
interval; DSB, double-strand break.
Table V. univariate and multivariate analyses for PFS in the 
distal colon.
 univariate Multivariate
 ------------------------------- ----------------------------------------------
Factor Median P-value HR (95% CI) P-value
Treatment cycles
  <10 8.8 0.009 0.46 (0.27-0.78) 0.004
  ≥10 14.5
CEA reduction ratio
  <0.6 13.5 0.2
  ≥0.6 12.6
Relative change
  <0.7 18.9 <0.001 2.23 (1.17-4.24) 0.014
  ≥0.7 9.7
MRE11
  Negative 18.9 0.077
  Positive 11.3
RAD51
  Negative 15.6 0.036 0.44 (0.15-1.37) 0.2
  Positive 10.1
DSB repair protein
expression pattern
  Defective 16.9 0.001 3.62 (1.09-11.99) 0.036
  Abundant 10.1
DSB, double-strand break.
IHARA et al:  DSB REPAIR PROTEIN EXPRESSION PREDICTS THE PROGNOSIS OF COLORECTAL CANCER1354
The cytotoxic reaction of oxaliplatin is dependent on DSBs. 
In DSBs defective cases, the chemotherapeutic effect of 
oxaliplatin may be greater. MRE11 and RAD51 are important 
components of homologous recombination, which functions 
in the repair of DSB. In the present study, we examined the 
correlation between the expression of these proteins and the 
chemotherapeutic effect in colorectal cancer patients. RAD51 
protein forms a helical nucleoprotein filament to promote 
DNA strand exchange and stimulate DNA-pairing activity, 
the basic steps of homologous recombination (21,22). In 
the present study, patients negative for MRE11 or RAD51 
expression obtained better size reduction of target lesions. We 
showed that RAD51-negative cases achieved longer survival 
times than positive cases. Several previous studies demon-
strated that RAD51 expression is correlated with resistance to 
chemotherapy and survival in various types of cancer such as 
lung, breast and esophageal cancer (23-25).
MRE11 is the core component of the MRN complex, 
the primary sensor of DSBs (12,13). In the present study, 
MRE11 expression was not an independent prognostic factor. 
The combined evaluation of MRE11, which acts as a sensor, 
and RAD51, which functions in repair, may lead to a better 
indication of the chemotherapeutic effect (Fig. 3). In fact, the 
relative change and PFS were significantly different between 
the defective pattern and abundant pattern, the expression 
pattern of DSB repair proteins.
We investigated the reason for the difference between 
MRE11 and RAD51 despite it also being a DSB repair protein, 
and postulated that some factors that may affect MRE11 
alone intervened in the result. MRE11 mutations occur in 
83.7% of MMR-defective primary colorectal cancers (26,27). 
Microsatellite instability (MSI) is displayed by ~15% of 
colorectal cancer cases, and high levels of MSI may be a 
predictive marker for lack of efficacy of fluorouracil-based 
therapy (28,29). This raises the possibility that some MRE11-
negative patients have poor prognosis as a consequence of their 
MSI status. We reviewed the subjects of our study with the 
exception of one case of tumor localization to a site proximal 
to the splenic flexure due to the association of high-frequency 
MSI with this tumor site (6). In this instance, MRE11 expres-
sion tended to be related to PFS, and DSB repair protein 
expression pattern is a factor that independently predicts PFS. 
In cases of tumor development in the distal colon, DSB repair 
protein expression may predict prognosis.
In the present study, we only examined cases with a 
targeted lesion to clarify associations with chemotherapeutic 
effect. Therefore, it is necessary to confirm expression in 
other cases. Moreover, we only investigated cases receiving 
oxaliplatin-based chemotherapy regimen as first-line treat-
ment since there were few cases undergoing other regimens 
as first-line treatment. In future studies, we will investigate the 
association between the expression of DSB repair proteins and 
the chemotherapeutic effect for other regimens, and compare 
these findings with the results of the present study.
In conclusion, cases with a defective pattern of DSB 
repair protein expression may possess higher sensitivity to 
chemotherapy for colorectal cancer. The expression pattern of 
DSB repair proteins may be a useful prognostic indicator for 
colorectal cancer patients.
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